Lilly begins Phase 2 test of LY3537021 for chemotherapy-induced nausea
The placebo-controlled, double-blind study is recruiting and keeps participants enrolled for roughly two months.
PR
By Priya Raman · Science Reporter
Oct 8 08:00 ETSource: ClinicalTrials.gov
The wire
- 01ClinicalTrials.gov lists NCT07169851, a Phase 2 double-blind placebo-controlled study of Eli Lilly's LY3537021 in adults with malignant disease, started 28 November 2025.
- 02Nausea and vomiting control is a live issue across Lilly's metabolic portfolio, and the trial tests the same emesis pathway in an oncology setting.
- 03The registry entry gives no enrolment target, dose or endpoint detail, and recruitment status can change before any readout.
From the source
Read at clinicaltrials.govA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851 · PHASE2 · RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions.
Source URL https://clinicaltrials.gov/study/NCT07169851
